From: |
|
Alison Bunce - Medicines and Healthcare Products Regulatory Agency
|
|
|
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
Title: |
|
CLASS 4 DRUG ALERT, FOR INFORMATION / ACTION, PHARMASWISS CESKA REPUBLIKA S.R.O (AN AFFILIATE OF BAUSCH AND LOMB UK LIMITED), EMERADE 150 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE; EMERADE 300 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE AND EMERADE 500 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
|
Broadcast content: |
|
Bausch & Lomb UK Limited has informed us of a risk of Emerade products failing to deliver a dose of Adrenaline from the syringe due to blockage of the needle. Since a recall of the products cannot be initiated at this time for a number of reasons, this Drug Alert has been classified as 'Class 4, For Information'. However, we are asking healthcare professionals to contact patients to ensure that they carry two pens on their person at all times and we have suggested a timeline of 72 hours for this action.
Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts |
|
Cascade to: |
|
- #GP#
- #ACCIDENTEMERGENCY#
- #COMMUNITYPHARMACISTS#
- #DISPENSING GP#
- #HospitalPharmacy#
|